My research is focused on developing NMR and other biophysical measurements to accurately and precisely define the structure, stability and dynamics of protein and RNA structural folds, ligand complexes and biomolecular interactions at a molecular level. In addition to enabling fundamental insights into biomolecular structure and function, our work aims to provide a validated measurement infrastructure that supports biopharmaceutical development and regulation. Our most recent work has focused on the development of NMR techniques for accurate and precise characterization of higher-order-structure (HOS) in biotherapeutics, in particular monoclonal antibodies, which are currently sought by industry for establishing consistency in drug manufacturing, detecting process-related drug-product variations and comparing biosimilars to innovator reference products. We are developing and demonstrating high-resolution NMR methods as simple, robust spectroscopic approaches for obtaining structural 'fingerprints' of the bioactive form(s) of protein therapeutics at atomic resolution in solution.
Department of Commerce Silver Medal Award 2007, 2016 and 2021
Hillebrand Prize 2021